In this population-based multistate cohort study of 814 987 men with prostate cancer followed up for up to 10 years, higher prevalence of county-level PSA screening in the 2 years prior to diagnosis was associated with lower odds of advanced stage cancer, all-cause mortality, and prostate cancer–specific mortality. This evidence concerns the gene KLK3 and prostate carcinoma.